Beyond the Blockade: One04 Therapeutics Redefines Rare Kidney Disease Treatment

FREIBURG, Germany – October 06, 2026 – For decades, the biopharmaceutical industry's approach to hyperactive immune responses has been fundamentally subtractive: find the overactive pathway and block it. This strategy of broad inhibition has yielded blockbuster drugs, but it often leaves patients vulnerable, trading one set of physiological problems for another. Today, the landscape of strategic innovation is shifting from blunt blockade to precise biological restoration. Nowhere is this transition more evident than in the evolving treatment paradigm for complement-mediated diseases, a niche but highly lucrative sector of modern medicine.

This morning, One04 Therapeutics GmbH & Co. KG, a clinical-stage biopharmaceutical company, announced that interim Phase 1 clinical data for its lead asset, CPV-104, has been accepted as a late-breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week in Denver, Colorado. The presentation, scheduled for October 22, marks the first time clinical data for a full-length recombinant human Factor H therapy will be shared with the global medical community. Following the conference, an international panel of key opinion leaders will convene virtually on October 26 to dissect the findings.

For investors and health policy analysts trying to understand the "why behind the buy" in today's biotech market, this announcement is a vital signal. It highlights a critical pivot in how we engineer complex biologics and how we conceptualize the treatment of severe, rare conditions like C3 glomerulopathy (C3G).

Restoring Nature's Brakes in the Complement Cascade

To understand the significance of CPV-104, one must first look at the underlying pathology of C3G. The disease is driven by a dysregulation of the alternative complement pathway, an ancient and essential part of the innate immune system. In healthy individuals, a protein known as Factor H acts as the system's primary regulator—a molecular brake that prevents the complement cascade from attacking the body's own tissues. In patients with C3G, this braking mechanism fails, leading to unchecked inflammation, the accumulation of protein deposits in the kidneys, and, ultimately, renal failure.

Historically, replacing this missing or defective Factor H has been a manufacturing nightmare. Full-length human Factor H is a massive, highly complex glycoprotein. Traditional eukaryotic expression systems, such as Chinese Hamster Ovary (CHO) cells or yeast, have consistently struggled to replicate the intricate post-translational modifications—specifically the unique glycosylation patterns—required for the protein to function stably and effectively in the human body.

This is where the intersection of industrial transformation and biotechnology becomes fascinating. One04 Therapeutics has bypassed traditional mammalian cell lines entirely, utilizing a proprietary moss-based manufacturing platform known as Bryotechnology. By cultivating the moss Physcomitrium patens in 500-liter single-use bioreactors, the company has achieved what was previously thought to be commercially unviable: the GMP-scale production of fully functional, recombinant human Factor H. This regional innovation, born out of the dense biotech ecosystem of Freiburg, Germany, allows CPV-104 to feature optimized glycosylation and improved pharmacokinetics, effectively solving a decades-old manufacturing bottleneck.

The Shifting Treatment Paradigm for C3 Glomerulopathy

As One04 Therapeutics steps onto the global nephrology stage, it enters a fiercely competitive arena. The race to solve C3G has attracted massive pharmaceutical players. Novartis is advancing iptacopan, an oral Factor B inhibitor, while Apellis Pharmaceuticals is exploring its C3 inhibitor, pegcetacoplan.

However, these competing therapies rely on the traditional subtractive model. By inhibiting specific components like Factor B or C3, they shut down broad sections of the complement cascade. While effective at halting the immediate damage to the kidneys, this broad immunosuppression can compromise the body's natural immune surveillance, leaving patients susceptible to severe bacterial infections.

CPV-104 represents a fundamental paradigm shift. As a first-in-class Factor H replacement, it does not block the cascade; it restores the endogenous regulation. Preclinical data published earlier this year demonstrated that CPV-104 could normalize serum C3 levels and clear pathogenic deposits while maintaining the immune system's ability to fight off pathogens.

The upcoming late-breaking presentation at ASN Kidney Week by Prof. Dr. Michael Wiesener of the University Hospital Erlangen will provide the first human validation of this approach. The data stems from a rigorous two-part Phase 1 trial. The single-ascending dose (SAD) portion, which evaluated 21 healthy volunteers across four cohorts, concluded with no dose-limiting toxicities or treatment-related serious adverse events. The medical community's eyes are now fixed on the interim safety, tolerability, and pharmacokinetic data from the first two cohorts of the multiple-ascending dose (MAD) portion, which involves 18 actual C3G patients.

From Stealth Spin-Out to Global Stage

The corporate maneuvering behind One04 Therapeutics is as strategic as its science. The company officially launched as an independent entity just last month, in September 2026, following a strategic spin-out of the clinical-stage Factor H program from its parent company, Eleva Biologics. Backed by undisclosed funding from the European venture capital fund D11Z.Ventures, the newly minted firm is executing a textbook example of the "pipeline-in-a-product" strategy.

Investors are not merely looking at a treatment for a rare kidney disease; they are evaluating a platform therapy for systemic complement dysregulation. Factor H deficiency is a known driver in several other high-value indications, most notably dry age-related macular degeneration (AMD) and geographic atrophy (GA)—conditions that affect millions globally and represent a massive unmet medical need.

The firm's management has explicitly stated that they are fully funded to key value inflection points, which include initiating an open-label Phase 2 study for C3G and a Phase 1 study for dry AMD and GA in early 2027. By hosting a virtual key opinion leader event immediately following the ASN presentation, featuring international heavyweights in nephrology and clinical pharmacology, the company is actively building the medical consensus necessary to secure the additional financing required for a larger, comparator-controlled Phase 2 study late next year.

As we navigate the complex biotech landscape of 2026, the story of One04 Therapeutics serves as a powerful case study. It illustrates how overcoming deep-seated manufacturing challenges can unlock entirely new therapeutic modalities. If the interim clinical data holds up to the rigorous scrutiny of the ASN audience, CPV-104 will not just offer hope for patients facing kidney failure; it will validate the broader industry shift toward therapies that heal by restoring natural balance rather than imposing artificial blockades.